SCHEMBL3011673

SCHEMBL3011673

COc1cccc(Cc2csc(N3CCC(S(=O)(=O)c4ccccc4Br)CC3)n2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.42
ALDH1A1 P00352 5/20 0.42
HSD17B10 Q99714 4/20 0.42
LMNA P02545 4/20 0.42
HPGD P15428 1/20 0.42
PTPRB P23467 1/20 0.40
CTSS P25774 1/20 0.38
USP2 O75604 1/20 0.38
RECQL P46063 1/20 0.38
TP53 P04637 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
HTT P42858 1/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3018818 0.93 TDP1 (0.42) MAPTALDH1A1HSD17B10LMNAHPGD
SCHEMBL3015110 0.90 L3MBTL1 (0.43) MAPTALDH1A1LMNAHPGDCTSS
SCHEMBL3006777 0.90 MAPT (0.44) MAPTALDH1A1HSD17B10LMNAHPGD
SCHEMBL3000401 0.89 CTSS (0.41) MAPTLMNAHPGDCTSSMAPK1
SCHEMBL3011280 0.89 CTSS (0.39) MAPTLMNACTSSTP53MAPK1
SCHEMBL3017061 0.88 CTSS (0.38) MAPTCTSSRECQLTP53TDP1
SCHEMBL3014368 0.87 MAPT (0.40) MAPTALDH1A1HSD17B10LMNAHPGD
SCHEMBL3012274 0.87 CTSS (0.43) MAPTALDH1A1HSD17B10LMNAHPGD
SCHEMBL3015950 0.87 DRD2 (0.39) MAPTALDH1A1HSD17B10LMNAHPGD
SCHEMBL3001082 0.87 MAPT (0.41) MAPTALDH1A1HSD17B10LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885ALDH1A1 3510/4885HSD17B10 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.